Randomized Phase II Study of Amrubicin as Single Agent or in Combination With Cisplatin Versus Etoposide-cisplatin as First-line Treatment in Patients With Extensive Stage SCLC (ES)
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Objective tumor response rate according to RECIST criteria measured every 2 cycles (every 6 weeks)
Until Disease Progression
No
Mary O'Brien, MD
Principal Investigator
Royal Marsden Hospital, London, UK
European Union: European Medicines Agency
EORTC Protocol 08062
NCT00388960
November 2006
December 2010
Name | Location |
---|